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ABSTRACT
ObjeCtives
To develop and validate updated QRISK3 prediction 
algorithms to estimate the 10 year risk of 
cardiovascular disease in women and men accounting 
for potential new risk factors.
Design
Prospective open cohort study.
setting
General practices in England providing data for the 
QResearch database.
PartiCiPants
1309 QResearch general practices in England: 981 
practices were used to develop the scores and a 
separate set of 328 practices were used to validate the 
scores. 7.89 million patients aged 25-84 years were in 
the derivation cohort and 2.67 million patients in the 
validation cohort. Patients were free of cardiovascular 
disease and not prescribed statins at baseline.
MethODs
Cox proportional hazards models in the derivation 
cohort to derive separate risk equations in men and 
women for evaluation at 10 years. Risk factors 
considered included those already in QRISK2 (age, 
ethnicity, deprivation, systolic blood pressure, body 
mass index, total cholesterol: high density lipoprotein 
cholesterol ratio, smoking, family history of coronary 
heart disease in a first degree relative aged less than 
60 years, type 1 diabetes, type 2 diabetes, treated 
hypertension, rheumatoid arthritis, atrial fibrillation, 
chronic kidney disease (stage 4 or 5)) and new risk 
factors (chronic kidney disease (stage 3, 4, or 5), a 
measure of systolic blood pressure variability 
(standard deviation of repeated measures), migraine, 
corticosteroids, systemic lupus erythematosus (SLE), 
atypical antipsychotics, severe mental illness, and 
HIV/AIDs). We also considered erectile dysfunction 
diagnosis or treatment in men. Measures of calibration 
and discrimination were determined in the validation 
cohort for men and women separately and for 
individual subgroups by age group, ethnicity, and 
baseline disease status.
Main OutCOMe Measures
Incident cardiovascular disease recorded on any of the 
following three linked data sources: general practice, 
mortality, or hospital admission records.
results
363 565 incident cases of cardiovascular disease were 
identified in the derivation cohort during follow-up 
arising from 50.8 million person years of observation. 
All new risk factors considered met the model 
inclusion criteria except for HIV/AIDS, which was not 
statistically significant. The models had good 
calibration and high levels of explained variation and 
discrimination. In women, the algorithm explained 
59.6% of the variation in time to diagnosis of 
cardiovascular disease (R2, with higher values 
indicating more variation), and the D statistic was 2.48 
and Harrell’s C statistic was 0.88 (both measures of 
discrimination, with higher values indicating better 
discrimination). The corresponding values for men 
were 54.8%, 2.26, and 0.86. Overall performance of 
the updated QRISK3 algorithms was similar to the 
QRISK2 algorithms.
COnClusiOn
Updated QRISK3 risk prediction models were 
developed and validated. The inclusion of additional 
clinical variables in QRISK3 (chronic kidney disease, a 
measure of systolic blood pressure variability 
(standard deviation of repeated measures), migraine, 
corticosteroids, SLE, atypical antipsychotics, severe 
mental illness, and erectile dysfunction) can help 
enable doctors to identify those at most risk of heart 
disease and stroke.
Introduction
The first QRISK model to estimate 10 year risk of cardio-
vascular disease was published in 2007.1  It was fol-
lowed by an updated model (QRISK2) in 2008, which 
included ethnic origin and additional risk factors (type 
2 diabetes, rheumatoid arthritis, atrial fibrillation, and 
chronic renal disease). Since then, QRISK2 has been 
updated annually and recalibrated to the latest version 
of the QResearch database2 ; the age range across which 
it applies has also been extended from 35-74 years to 
WhAT IS AlReAdy knoWn on ThIS TopIC
Methods to identify patients at increased risk of cardiovascular disease (CVD) are 
needed to identify those for whom interventions or more frequent assessment may 
be required
QRISK2 algorithms are widely used to estimate the 10 year risks of CVD in people 
aged 25-84 taking account of information recorded in primary care electronic 
records and that the patient can also provide
WhAT ThIS STudy AddS
Updated algorithms (QRISK3) quantify the absolute risks of CVD in people aged 
25-84, which include established and new risk factors
New factors are an expanded definition of chronic kidney disease (stage 3, 4, or 5), 
migraine, corticosteroid use, systemic lupus erythematosus, atypical antipsychotic 
use, severe mental illness, erectile dysfunction, and a measure of blood pressure 
variability (standard deviation of repeated measures)
The updated risk algorithms provide valid measures of absolute risk in the general 
population of patients as shown by the performance in a separate validation cohort
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25-84 years, type 1 diabetes has been included as a sep-
arate variable, smoking is assessed at five levels instead 
of two, and the Townsend score has been updated using 
the most recent values from the 2011 census. This helps 
to ensure that the algorithms reflect the changes in pop-
ulation characteristics (such as changes in prevalence 
of smoking, body mass index, or declining incidence of 
cardiovascular disease) and improvements in data 
quality (such as improved recording of risk factors and 
data linkage to Hospital Episode Statistics,3  which has 
increased ascertainment of cardiovascular events4 ). 
The QRISK algorithms have been validated by ourselves 
and others in independent groups of patients using UK 
primary care databases such as QResearch,4  Clinical 
Practice Research Datalink (CPRD),4  The Health 
Improvement Network (THIN),5-9  and clinical 
cohorts10-12  as well as in international populations.13 14 
Their use has been evaluated in observational studies,15 
cost effectiveness evaluations,16  and clinical trials.17 18
QRISK2 is now used across England’s health service 
(NHS England) and recommended in the NHS Quality 
and Outcomes Framework,19  guidance from the 
National Institute of Health and Care Excellence,20  and 
NHS Health Check.21 QRISK2 is also used in occupa-
tional health settings and internationally, with over two 
million hits on the QRISK website (www.qrisk.org). A 
new NICE guideline on lipid modification and cardio-
vascular risk assessment was published in 2014.20  This 
guideline highlighted a number of conditions associ-
ated with increased cardiovascular risk that may not be 
fully captured by QRISK2, including HIV/AIDS, stage 3 
kidney disease, systemic lupus erythematosus (SLE), 
severe mental illness, and use of atypical antipsychot-
ics or corticosteroids.20  These conditions are not specif-
ically identified within QRISK2, which may result in 
underestimation of risk in the relevant patient groups. 
In addition, recently published research has high-
lighted increased cardiovascular risk and potential 
prognostic importance for erectile dysfunction,22-24 
migraine,25  and blood pressure variability.26 We there-
fore derived and validated a new version of the algo-
rithms, QRISK3, to determine whether these factors 
should be incorporated into the algorithms to improve 
estimation of cardiovascular risk for these patients.
Methods
study design and data source
Using the QResearch database (version 41) we undertook 
a cohort study in a large population of primary care 
patients. We included all practices in England that had 
been using the EMIS computer system for at least one 
year and randomly allocated three quarters of practices 
to the derivation dataset and the remainder to a valida-
tion dataset. We identified an open cohort of patients 
aged 25-84 years registered with the practices between 1 
January 1998 and 31 December 2015. Patients were 
excluded if they had no postcode related Townsend score 
(since these usually result from patients moving to newly 
built houses with new postcodes not being yet linked to 
deprivation data or from patients being homeless or not 
having a permanent residence), had pre-existing 
 cardiovascular disease (on general practice records or 
linked hospital records), or were using prescribed statins 
at cohort entry. We determined an entry date to the 
cohort for each patient, which was the latest of the fol-
lowing: 25th birthday, date of registration with the prac-
tice plus one year, date on which the practice computer 
system was installed plus one year, or the study start date 
(1 January 1998). Patients were censored at the earliest 
date of the diagnosis of cardiovascular disease, death, 
deregistration with the practice, last upload of comput-
erised data, or study end date (31 December 2015).
Outcomes
Our outcome was cardiovascular disease, which was 
defined as a composite outcome of coronary heart dis-
ease, ischaemic stroke, or transient ischaemic attack. The 
QResearch database is linked at individual patient level to 
hospital admissions data (Hospital Episode Statistics), 
and mortality records obtained from the Office for 
National Statistics. The records are linked using a pseud-
onymised NHS number specific to the QResearch data-
base. The recording of NHS numbers is valid and 
complete for 99.8% of patients with data on QResearch, 
99.9% for ONS mortality records, and 98% for hospital 
admissions records.3 27  We classified patients as having 
cardiovascular disease if there was a record of the rele-
vant clinical code in either their general practice record, 
their linked hospital record, or their linked mortality 
record. We used Read codes to identify cardiovascular 
disease cases from the general practice record. The Read 
codes are listed in table 1 of the web appendix. We used 
ICD-10 (international classification of diseases, 10th revi-
sion) clinical codes to identify cases from hospital and 
mortality records except for the three years between 1 Jan-
uary 1998 and 31 December 2000, when ICD-9 was in use 
for mortality records. The ICD-10 codes used were G45 
(transient ischaemic attack and related syndromes), I20 
(angina pectoris), I21 (acute myocardial infarction), I22 
(subsequent myocardial infarction), I23 (complications 
after myocardial infarction), I24 (other acute ischaemic 
heart disease), I25 (chronic ischaemic heart disease), I63 
(cerebral infarction), and I64 (stroke not specified as hae-
morrhage or infarction). The corresponding ICD-9 codes 
used were 410, 411, 412, 413, 414, 434, and 436. General 
practice and linked mortality and Hospital Episode Statis-
tics data were available until 31 December 2015. We used 
the earliest recorded date of cardiovascular disease on 
any of the three data sources as the outcome date.
Predictor variables
We examined the predictor variables in box 1 based on 
established risk factors already included in the current 
version of QRISK2 and new candidate variables high-
lighted in the literature or National Institute for Health 
and Care Excellence guidelines.
From the general practice record we extracted data for 
demographic factors, clinical diagnoses, and clinical 
values. For clinical values (systolic blood pressure and 
body mass index) and smoking status we obtained the 
most recent values recorded before the baseline date. We 
selected the closest value to cohort entry for total choles-
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terol: high density lipoprotein cholesterol ratio, restrict-
ing values after the baseline date to those before the 
patient had a diagnosis of cardiovascular disease or was 
censored, and before any statin  prescriptions. To assess 
variability in systolic blood pressure, we identified all 
systolic blood pressure values recorded in the five years 
before study entry and calculated the standard devia-
tion where there were two or more recorded values. Use 
of drugs at baseline was defined as at least two prescrip-
tions, with the most recent one no more than 28 days 
before the date of entry to the cohort. All other predictor 
variables were based on the latest information recorded 
in the general practice record before entry to the cohort.
Derivation and validation of the models
We developed and validated the risk prediction 
 algorithms using established methods1 5 8 10 28  and 
 performed an initial analysis based on patients with 
complete variables. For our main analysis, we used 
multiple imputation with chained equations to replace 
missing values for body mass index, systolic blood pres-
sure, standard deviation of systolic blood pressure, 
serum cholesterol, high density lipoprotein cholesterol, 
and smoking status and used these values in our main 
analyses.29-32  We log transformed values for continuous 
variables that were not normally distributed for inclu-
sion in the imputation model so that the imputed values 
would better match the distribution of observed values. 
Five imputations were carried out as this has a relatively 
high efficiency33 and was a pragmatic approach 
accounting for the size of the datasets and capacity of 
the available servers and software. In the imputation 
model we included all predictor variables, along with 
age interaction terms, the Nelson-Aalen estimator of the 
baseline cumulative hazard, and the outcome indicator.
Cox’s proportional hazards models were used to 
estimate the coefficients for each risk factor in women 
and men separately. We used Rubin’s rules to com-
bine the results across the imputed datasets.34  Frac-
tional polynomials35 were used to model non-linear 
risk relations with continuous variables using data 
from patients with recorded values to derive the frac-
tional polynomial terms. We fitted full models ini-
tially. For consistency, we included variables from 
existing QRISK2 models and then retained additional 
variables if they had an adjusted hazard ratio of less 
than 0.90 or greater than 1.10 (for binary variables) 
and were statistically significant at the 0.01 level. We 
developed three main models. Model A contains the 
same variables as the latest version of QRISK2-2017. 
Model B includes the additional variables that met 
our inclusion criteria but not the standard deviation 
of serial systolic blood pressure values. Model C is the 
same as model B except that it includes the standard 
deviation of serial systolic blood pressure values. We 
examined interactions between new predictor vari-
ables and age at study entry and included significant 
interactions in models B and C along with interac-
tions already included in QRISK2.
From the final models we used the regression coeffi-
cients for each variable as weights, which we combined 
with the baseline survivor function evaluated up to 15 
years to derive risk equations over a period of 15 years of 
follow-up.36 This enabled us to derive risk estimates for 
each year of follow-up, with a specific focus on 10 year 
risk estimates. We estimated the baseline survivor func-
tion based on zero values of centred continuous vari-
ables, with all binary predictor values set to zero.
validation of the models
In the validation cohort we used multiple imputation 
to replace missing values for body mass index, systolic 
blood pressure, standard deviation of systolic blood 
pressure, serum cholesterol, high density lipoprotein 
cholesterol, and smoking status. We carried out five 
imputations. The risk equations for women and men 
obtained from the derivation cohort for models A, B, 
and C were applied to the validation cohort and 
box 1: variables used in QrisK algorithms
existing variables from QrisK2-2017
Age at study entry (baseline)
Ethnic origin (nine categories)
Deprivation (as measured by the Townsend score, where higher values indicate higher 
levels of material deprivation)
Systolic blood pressure
Body mass index
Total cholesterol: high density lipoprotein cholesterol ratio
Smoking status (non-smoker, former smoker, light smoker (1-9/day), moderate 
smoker (10-19/day), or heavy smoker (≥20/day))
Family history of coronary heart disease in a first degree relative aged less than 60 years
Diabetes (type 1, type 2, or no diabetes)
Treated hypertension (diagnosis of hypertension and treatment with at least one 
antihypertensive drug)
Rheumatoid arthritis (diagnosis of rheumatoid arthritis, Felty’s syndrome, Caplan’s 
syndrome, adult onset Still’s disease, or inflammatory polyarthropathy not otherwise 
specified)
Atrial fibrillation (including atrial fibrillation, atrial flutter, and paroxysmal atrial fibrillation)
Chronic kidney disease (stage 4 or 5) and major chronic renal disease (including 
nephrotic syndrome, chronic glomerulonephritis, chronic pyelonephritis, renal 
dialysis, and renal transplant)
new or amended risk factors considered
Expanded definition of chronic kidney disease (to include general practitioner 
recorded diagnosis of chronic kidney disease stage 3 in addition to stages 4 and 5 as 
well as major chronic renal disease)
Measure of systolic blood pressure variability (standard deviation of repeated measures)
Diagnosis of migraine (including classic migraine, atypical migraine, abdominal 
migraine, cluster headaches, basilar migraine, hemiplegic migraine, and migraine 
with or without aura)
Corticosteroid use (British National Formulary (BNF) chapter 6.3.2 including oral or 
parenteral prednisolone, betamethasone, cortisone, depo-medrone, dexamethasone, 
deflazacort, efcortesol, hydrocortisone, methylprednisolone, or triamcinolone)
Systemic lupus erythematosus (including diagnosis of SLE, disseminated lupus 
erythematosus, or Libman-Sacks disease)
Second generation “atypical” antipsychotic use (including amisulpride, aripiprazole, 
clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, 
or zotepine)
Diagnosis of severe mental illness (including psychosis, schizophrenia, or bipolar 
affective disease)
Diagnosis of HIV or AIDS
Diagnosis of erectile dysfunction or treatment for erectile dysfunction (BNF chapter 7.4.5 
including alprostadil, phosphodiesterase type 5 inhibitors, papaverine, or phentolamine)
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 measures of discrimination calculated. As in previous 
 studies,4 we calculated R2 values (explained variation 
where higher values indicate a greater proportion of 
variation in time to cardiovascular disease diagnosis is 
explained by the model 37 ), D statistic38  (a measure of 
discrimination where higher values indicate better dis-
crimination), and Harrell’s C statistic at 10 years and 
combined these across datasets using Rubin’s rules. 
Harrell’s C statistic39 is a measure of discrimination 
that is similar to the area under a receiver operating 
characteristic curve but takes account of the censored 
nature of the data.
We assessed calibration (comparing the mean pre-
dicted risks at 10 years with the observed risk by 10th of 
predicted risk). The observed risks were obtained using 
the Kaplan-Meier estimates evaluated at 10 years. We 
also evaluated performance in each age group (<40, 
40-59, ≥60 years), ethnic origin subgroup, and each 
comorbidity and treatment subgroup. Performance was 
also evaluated by calculating Harrell’s C statistics in 
individual general practices and combining the results 
using meta-analytical techniques for comparison with 
a previous study of QRISK2.9
reclassification statistics
In line with current NICE guidelines,20 we classified 
patients as being at high risk of cardiovascular disease if 
their 10 year risk was 10% or greater. We compared pre-
dicted risks for our final models (QRISK3) with the latest 
version of QRISK2-2017 to determine the percentage of 
patients who would be reclassified at this threshold 
according to each model. Among the reclassified patients 
we also calculated the observed risks of cardiovascular 
disease at 10 years using the Kaplan-Meier method.
To maximise the power and generalisability of the 
results we used all the relevant patients on the data-
base. STATA (version 14) was used for all analyses. The 
study adhered to the TRIPOD (Transparent Reporting of 
a multivariable prediction model for Individual Progno-
sis Or Diagnosis) statement for reporting.40
Patient involvement
Over the past 10 years since the original publication of 
QRISK1  there has been extensive discussion about 
methods for assessment of cardiovascular risk. This has 
included a series of public stakeholder consultations in 
relation to updates of NICE guidance on lipid modifica-
tion,20  the NHS Quality and Outcomes Framework, and 
NHS Health Check.21 We therefore decided to focus on 
issues highlighted in NICE guidance and the literature 
rather than to consult patient or professional groups. 
We decided it would be more transparent and effective 
to discuss the addition of new variables once the paper 
was published and the relative contribution of individ-
ual risk factors had been quantified. Given the wide-
spread implementation of QRISK2 across the NHS and 
its inclusion in guidelines, this would give time for feed-
back from a range of stakeholders (including patient 
groups and charities) as to which changes would 
be  most beneficial and how improvements might be 
implemented. 
Results
study population
Overall, 1309 practices contributing to the QResearch 
database in England met our inclusion criteria. Of 
these, 981 were randomly assigned to the derivation 
dataset and the remainder (n=328) to a validation 
cohort. For the derivation cohort we identified 8 602 833 
patients aged 25-84 years. We excluded 31 433 (0.4%) 
with no recorded Townsend score, 344 669 (4.0%) with 
a diagnosis of cardiovascular disease at baseline 
recorded on the general practice or Hospital Episode 
Statistics record, and 336 928 (3.9%) prescribed statins 
at baseline. Overall, 7 889 803 patients were included in 
the derivation analysis.
For the validation cohort we identified 2 918 082 
patients aged 25-84 years. We excluded 13 862 (0.5%) 
with no recorded Townsend score, 118 057 (4.0%) with a 
diagnosis of cardiovascular disease recorded on the 
general practice or Hospital Episode Statistics record, 
and 114 865 (3.9%) prescribed statins at baseline. In 
total, 2 671 298 patients were included in the validation 
analysis.
baseline characteristics
Table 1  shows the baseline characteristics of men and 
women in the derivation and validation cohorts. In the 
derivation cohort, self assigned ethnic origin was 
recorded for 64.9% of women and 59.7% of men, smok-
ing status for 85.0% and 77.7%, respectively, systolic 
blood pressure for 82.8% and 68.3%, respectively, body 
mass index for 72.8% and 64.0%, respectively, and total 
cholesterol: high density lipoprotein cholesterol ratio 
for 39.8% and 37.9%, respectively. Complete informa-
tion for smoking status, systolic blood pressure, body 
mass index, and total cholesterol: high density lipopro-
tein cholesterol ratio was provided for 28.5% of women 
and 24.6% of men. At least two systolic blood pressures 
were recorded for 77.7% of women and 64.0% of men 
from which the standard deviations were calculated. 
These values were similar to corresponding values for 
both sexes in the validation cohort (table 1).
Table 1 also shows comorbidities at study entry. For 
the new variables of interest, severe mental illness was 
recorded for 6.8% of women and 4.3% of men, migraine 
for 6.4% and 2.7%, respectively, chronic kidney disease 
(stage 3, 4, or 5) for 0.5% and 0.3%, respectively; pre-
scribed atypical antipsychotics for 0.5% of women and 
men, and prescribed corticosteroids for 2.4% and 1.5%, 
respectively, and 2.3% of men had a diagnosis of or 
treatment for erectile dysfunction. SLE was recorded for 
0.1% of women and less than 0.1% of men and HIV/AIDS 
for 0.1% of women and 0.2% of men. The mean of the 
most recent systolic blood pressure values was 123.2 
mm Hg in women and 129.2 mm Hg in men and the 
mean of the standard deviations of repeated systolic 
blood pressure values was 9.3 in women and 9.9 in men.
incidence rates of cardiovascular disease
Table 2  shows the numbers of patients with a new diag-
nosis of cardiovascular disease during follow-up by age 
group (five year intervals) in women and men in the 
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table 3 | adjusted hazard ratios (95% confidence interval) for cardiovascular disease in women in the derivation cohort
Predictor variables Model a* Model b† Model C‡
Townsend score (per 5 unit increase)§ 1.48 (1.46 to 1.51) 1.47 (1.45 to 1.50) 1.47 (1.45 to 1.50)
Ethnic origin:
 White or not recorded 1.00 1.00 1.00
 Indian 1.32 (1.26 to 1.38) 1.32 (1.26 to 1.39) 1.32 (1.26 to 1.39)
 Pakistani 1.76 (1.66 to 1.87) 1.76 (1.66 to 1.87) 1.76 (1.66 to 1.86)
 Bangladeshi 1.33 (1.23 to 1.44) 1.35 (1.25 to 1.46) 1.34 (1.24 to 1.45)
 Other Asian 1.07 (0.985 to 1.16) 1.08 (0.995 to 1.17) 1.08 (0.992 to 1.17)
 Black Caribbean 0.836 (0.791 to 0.884) 0.844 (0.798 to 0.892) 0.843 (0.797 to 0.891)
 Black African 0.660 (0.605 to 0.721) 0.677 (0.620 to 0.740) 0.675 (0.618 to 0.737)
 Chinese 0.710 (0.612 to 0.823) 0.726 (0.625 to 0.842) 0.722 (0.622 to 0.837)
 Other 0.836 (0.786 to 0.890) 0.843 (0.792 to 0.897) 0.843 (0.791 to 0.897)
Smoking status§:
 Non-smoker 1.00 1.00 1.00
 Former smoker 1.16 (1.12 to 1.19) 1.14 (1.11 to 1.18) 1.14 (1.11 to 1.18)
 Light smoker 1.79 (1.73 to 1.85) 1.76 (1.70 to 1.82) 1.75 (1.70 to 1.81)
 Moderate smoker 1.98 (1.91 to 2.05) 1.95 (1.88 to 2.02) 1.95 (1.88 to 2.02)
 Heavy smoker 2.39 (2.30 to 2.49) 2.34 (2.25 to 2.44) 2.34 (2.25 to 2.43)
Medical characteristics:
 Family history of coronary heart disease in first degree relative <60 years§ 1.59 (1.56 to 1.63) 1.58 (1.54 to 1.61) 1.58 (1.54 to 1.61)
 Type 1 diabetes§ 5.66 (5.11 to 6.26) 5.66 (5.12 to 6.26) 5.62 (5.08 to 6.22)
 Type 2 diabetes§ 2.95 (2.76 to 3.15) 2.92 (2.73 to 3.13) 2.91 (2.72 to 3.11)
 Treated hypertension§ 1.75 (1.68 to 1.82) 1.71 (1.64 to 1.78) 1.66 (1.60 to 1.73)
 Rheumatoid arthritis 1.32 (1.28 to 1.36) 1.24 (1.21 to 1.28) 1.24 (1.20 to 1.27)
 Atrial fibrillation§ 5.09 (4.35 to 5.95) 4.94 (4.23 to 5.78) 4.92 (4.20 to 5.75)
 Chronic kidney disease (stage 4 or 5)§ 2.31 (2.02 to 2.65) NA NA
 Chronic kidney disease (stage 3, 4, or 5)§ NA 1.94 (1.72 to 2.19) 1.92 (1.70 to 2.17)
 Migraine§ NA 1.36 (1.31 to 1.41) 1.35 (1.30 to 1.40)
 Corticosteroid use§ NA 1.82 (1.74 to 1.90) 1.81 (1.74 to 1.89)
 Systemic lupus erythematosus§ NA 2.15 (1.79 to 2.57) 2.14 (1.78 to 2.56)
 Atypical antipsychotic use NA 1.29 (1.21 to 1.38) 1.29 (1.21 to 1.37)
 Severe mental illness NA 1.14 (1.11 to 1.16) 1.13 (1.11 to 1.16)
Total cholesterol: HDL cholesterol ratio (per unit increase) 1.17 (1.16 to 1.17) 1.17 (1.16 to 1.17) 1.17 (1.16 to 1.17)
Systolic blood pressure (per 20 unit increase) 1.14 (1.14 to 1.15) 1.15 (1.14 to 1.15) 1.14 (1.13 to 1.15)
Standard deviation of blood pressure (per 10 unit increase) NA NA 1.08 (1.07 to 1.09)
NA=not applicable; HDL=high density lipoprotein.
*Includes chronic kidney disease (stage 4 or 5) fractional polynomial terms for age (age and age−2) and body mass index (BMI−2 and BMI−2ln(BMI)), and interactions with age for body mass index, 
systolic blood pressure, Townsend score, family history of coronary heart disease, treated hypertension, atrial fibrillation, type 1 diabetes, type 2 diabetes, chronic kidney disease, and smoking 
status.
†Same as model A with chronic kidney disease (stage 3, 4, or 5), extra variables listed in table, and additional age interactions for: migraine, corticosteroid use, and systemic lupus 
erythematosus.
‡Same as model B but with standard deviation of systolic blood pressure.
§Interaction with age; hazard ratios evaluated at mean age.
table 2 | incidence rates of cardiovascular disease per 1000 person years in derivation cohort
age group (years)
Women Men
incident cases Person years
rate per 1000 person 
years (95% Ci) incident cases Person years
rate per 1000 person 
years (95% Ci)
25-29 832 3 455 662 2.4 (2.2 to 2.6) 1351 3 379 716 4 (3.8 to 4.2)
30-34 1878 3 802 577 4.9 (4.7 to 5.2) 3823 3 880 890 9.9 (9.5 to 10.2)
35-39 3636 3 551 460 10.2 (9.9 to 10.6) 7963 3 748 285 21.2 (20.8 to 21.7)
40-44 5651 2 971 995 19 (18.5 to 19.5) 12 750 3 192 048 39.9 (39.3 to 40.6)
45-49 8272 2 581 104 32 (31.4 to 32.7) 17 763 2 672 642 66.5 (65.5 to 67.4)
50-54 12 022 2 490 263 48.3 (47.4 to 49.1) 24 040 2 437 106 98.6 (97.4 to 99.9)
55-59 14 524 1 944 140 74.7 (73.5 to 75.9) 25 464 1 796 342 141.8 (140.0 to 143.5)
60-64 18 471 1 625 795 113.6 (112.0 to 115.3) 27 021 1 372 104 196.9 (194.6 to 199.3)
65-69 22 510 1 314 303 171.3 (169.0 to 173.5) 26 903 1 013 291 265.5 (262.3 to 268.7)
70-74 25 462 1 015 263 250.8 (247.7 to 253.9) 24 549 691 866 354.8 (350.4 to 359.3)
75-79 26 883 765 681 351.1 (346.9 to 355.3) 19 820 438 861 451.6 (445.4 to 458.0)
80-84 20 408 424 994 480.2 (473.7 to 486.8) 11 569 198 481 582.9 (572.4 to 593.6)
Total 160 549 25 943 236 61.9 (61.6 to 62.2) 203 016 24 821 632 81.8 (81.4 to 82.1)
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 derivation cohort based on the linked general practice, 
hospital, and Office for National Statistics morality 
records. In the derivation cohort, we identified 363 565 
incident cases of cardiovascular disease arising from 
50.8 million person years of observation. The incidence 
of cardiovascular disease increased steeply by age 
group and values were higher in men than women for 
all age groups. Table 2 in the web appendix shows a 
similar breakdown by nine ethnic groups. For example, 
4758 events occurred in Indian women and men arising 
from 8 819 177 person years of observation and 417 
events in Chinese women and men arising from 210 267 
person years of observation.
Table 3 in the web appendix shows the source of the 
data that first identified the incident event by type of 
event in the derivation cohort. It also shows the number 
and percentage of cases that were identified only using 
general practice data with no subsequent evidence of 
cardiovascular disease on hospital or mortality records. 
Of the 363 565 incident events, 78 327 (21.5%) were myo-
cardial infarction, 152 141 (41.8%) were angina, 49 504 
(13.6%) were transient ischaemic attack, and 83 593 
(23.0%) were ischaemic strokes. Overall, 92 936 (25.6% 
of all 363 565 events) were only recorded on the general 
practice record, with the most common condition being 
transient ischaemic attack (27 227 events).
The median follow-up in the derivation cohort was 4.4 
years (interquartile range 1.6-10.8) and 2 141 841 patients 
had 10 years or more of follow-up and 1 090 704 had 15 
years or more of follow-up. Of the 7 889 803 patients in 
the derivation cohort, 696 387 (8.8%) started using 
statins after entry to the cohort and before having a new 
diagnosis of cardiovascular disease or being censored. 
Of the 50 764 868 person years of follow-up, 46 940 777 
person years were free from statin use (92.5%).
In the validation cohort, the median follow up was 
4.4 years (interquartile range 1.6-10.8) and 728 704 
patients had 10 years or more of follow-up and 380 387 
had 15 years or more of follow-up. 
Predictor variables
Table 3  shows the adjusted hazard ratios for women in 
the derivation cohort and table 4 shows the correspond-
ing values for men. Of the new risk factors, all met our 
model inclusion criteria except for HIV/AIDS, which 
was associated with a 25% increased risk in women and 
17% increased risk in men, but these were not statisti-
cally significant at the 0.01 level. Model A is the latest 
version of QRISK2 (2017). Model B includes the addi-
tional variables that met our inclusion criteria. Model C 
is the same as model B except that it includes the stan-
dard deviation of serial systolic blood pressure values.
The supplementary figure shows graphs of the 
adjusted hazard ratios for model B for the fractional 
polynomial terms for age and body mass index as well 
as the interaction terms between age and relevant pre-
dictor variables, as listed in the footnotes of tables 3 
and 4 . For the new variables of interest in model B, 
migraine was associated with a 36% increased risk of 
cardiovascular disease for women and a 29% increased 
risk for men, corticosteroids were associated with an 
82% increased risk for women and 58% increased risk 
for men, SLE was associated with a 115% increased risk 
for women and a 55% increased risk for men, atypical 
antipsychotics were associated with a 29% increased 
risk for women and a 15% increased risk for men, 
severe mental illness was associated with a 14% 
increased risk for women and a 13% increased risk for 
men. Erectile dysfunction was associated with a 25% 
increased risk. Where there were age interactions these 
values relate to risks evaluated at the mean ages. The 
full list of age interactions is shown in the footnotes for 
tables 3 and 4. For the new variables, there were statis-
tically significant interactions between age and 
migraine as well as age and corticosteroid use in both 
sexes. In women, there was also a statistically signifi-
cant interaction between age and SLE. In men, there 
was also a statistically significant interaction between 
age and erectile dysfunction. For each of these interac-
tions, hazard ratios for the predictors were higher at 
younger ages compared with older ages, except for 
erectile dysfunction in men, where hazard ratios were 
highest for men aged around age 45 and then declined 
gradually with increasing age.
For model C, the standard deviation of systolic 
blood pressure values was included in the model in 
addition to the single most recent systolic blood pres-
sure value. Overall a 10 unit increase in the standard 
deviation of systolic blood pressure was associated 
with an 8% increased risk of cardiovascular disease in 
women (table 3 ) and an 11% increased risk in men 
(table 4).
Tables 4 and 5 in the web appendix show the results 
of complete case analyses for models B and C for 
women and men, respectively (ie, the results based on 
patients with complete data). The hazard ratios associ-
ated with total cholesterol: high density lipoprotein 
cholesterol ratio, systolic blood pressure, and standard 
deviation of systolic blood pressure were similar to 
those obtained in the main models using multiply 
imputed data.
validation
Discrimination
Table 5 shows the performance of each algorithm in the 
validation cohort for women and men for each of mod-
els A, B, and C. For model B in women, the algorithm 
explained 59.5% of the variation in time to diagnosis of 
cardiovascular disease (R2), the D statistic was 2.48, and 
the Harrell’s C statistic was 0.88. The corresponding 
values for men were 54.8%, 2.26, and 0.86. Measures of 
performance were similar for all three models.
Table 6 in the web appendix shows the validation sta-
tistics for model B in various subgroups, including 
three age groups, ethnic groups, and in those with spe-
cific comorbidities. The highest performance values by 
ethnic origin were in Chinese women (R2=64.7%; 
D=2.77; Harrell’s C=0.91) and the lowest values were in 
Caribbean women (R2=51.6%; D=2.11; Harrell’s C=0.85). 
Performance values were highest in the youngest age 
group (25-39 years) and lowest in the oldest age group 
(60-84 years).
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For the subgroup of women with type 1 diabetes the R2 
was 47.3%, D statistic was 1.94, and Harrell’s C  statistic was 
0.82. The corresponding values for men with type 1 diabe-
tes were 45.6%, 1.87, and 0.80. For the subgroup of women 
with type 2 diabetes the R2 was 25.2%, D statistic was 1.19, 
and Harrell’s C statistic was 0.70. The corresponding val-
ues for men with type 2 diabetes were 22.9%, 1.12, and 0.70.
Figure 1 shows the funnel plots of Harrell’s C statistic 
for model B across the 328 practices in the validation 
cohort. The funnel plots show Harrell’s C statistic for 
each general practice versus the number of cardiovas-
cular events in each practice in women and men sepa-
rately. Practices with fewer cardiovascular events had 
wider variation in the C statistic than practices with 
more events. The summary (average) C statistic for 
women was 0.874 (95% confidence interval 0.869 to 
0.880) from a random effects meta-analysis. The I2 
value (ie, the percentage of total variation in C statistics 
table 4 | adjusted hazard ratios (95% confidence interval) for cardiovascular disease in men in the derivation cohort
Predictor variables Model a* Model b† Model C‡
Townsend score (per 5 unit increase)§ 1.19 (1.17 to 1.20) 1.18 (1.17 to 1.20) 1.18 (1.17 to 1.20)
Ethnic origin:
 White or not recorded 1.00 1.00 1.00
 Indian 1.31 (1.26 to 1.36) 1.32 (1.27 to 1.37) 1.32 (1.27 to 1.37)
 Pakistani 1.62 (1.54 to 1.69) 1.61 (1.53 to 1.68) 1.61 (1.53 to 1.68)
 Bangladeshi 1.70 (1.61 to 1.79) 1.70 (1.62 to 1.80) 1.70 (1.61 to 1.79)
 Other Asian 1.03 (0.968 to 1.10) 1.04 (0.970 to 1.11) 1.04 (0.970 to 1.11)
 Black Caribbean 0.700 (0.663 to 0.738) 0.700 (0.663 to 0.739) 0.699 (0.662 to 0.738)
 Black African 0.671 (0.623 to 0.722) 0.672 (0.625 to 0.724) 0.670 (0.623 to 0.721)
 Chinese 0.652 (0.574 to 0.740) 0.66 (0.581 to 0.749) 0.660 (0.582 to 0.749)
 Other 0.770 (0.729 to 0.814) 0.77 (0.729 to 0.813) 0.769 (0.728 to 0.812)
Smoking status§:
 Non-smoker 1.00 1.00 1.00
 Former smoker 1.22 (1.19 to 1.25) 1.21 (1.18 to 1.24) 1.21 (1.18 to 1.24)
 Light smoker 1.75 (1.71 to 1.79) 1.74 (1.70 to 1.78) 1.74 (1.70 to 1.78)
 Moderate smoker 1.91 (1.86 to 1.96) 1.90 (1.85 to 1.95) 1.89 (1.84 to 1.94)
 Heavy smoker 2.22 (2.16 to 2.29) 2.21 (2.14 to 2.28) 2.20 (2.14 to 2.27)
Medical characteristics:
 Family history of coronary heart disease in first degree relative <60 years§ 1.73 (1.7 to 1.76) 1.72 (1.69 to 1.75) 1.72 (1.69 to 1.75)
 Type 1 diabetes§ 3.59 (3.31 to 3.90) 3.47 (3.20 to 3.77) 3.44 (3.17 to 3.73)
 Type 2 diabetes§ 2.42 (2.29 to 2.57) 2.37 (2.24 to 2.51) 2.36 (2.23 to 2.50)
 Treated hypertension§ 1.76 (1.69 to 1.83) 1.73 (1.67 to 1.80) 1.68 (1.61 to 1.74)
 Rheumatoid arthritis 1.30 (1.25 to 1.35) 1.24 (1.19 to 1.28) 1.23 (1.19 to 1.28)
 Atrial fibrillation§ 2.46 (2.18 to 2.78) 2.44 (2.16 to 2.76) 2.42 (2.14 to 2.73)
 Chronic kidney disease (stage 4 or 5)§ 2.39 (2.13 to 2.68) NA NA
 Chronic kidney disease (stage 3, 4, or 5)§ NA 2.09 (1.87 to 2.34) 2.05 (1.83 to 2.29)
 Migraine§ NA 1.29 (1.24 to 1.35) 1.29 (1.24 to 1.34)
 Corticosteroid use§ NA 1.58 (1.51 to 1.66) 1.58 (1.5 to 1.66)
 Systemic lupus erythematosus NA 1.55 (1.15 to 2.10) 1.55 (1.15 to 2.10)
 Atypical antipsychotic use NA 1.15 (1.07 to 1.23) 1.14 (1.06 to 1.22)
 Severe mental illness NA 1.13 (1.11 to 1.16) 1.13 (1.10 to 1.15)
 Erectile dysfunction or treatment§ NA 1.25 (1.18 to 1.33) 1.25 (1.18 to 1.33)
Total cholesterol: HDL cholesterol ratio (per unit increase) 1.19 (1.18 to 1.19) 1.19 (1.18 to 1.19) 1.19 (1.18 to 1.19)
Systolic blood pressure (per 20 unit increase) 1.14 (1.13 to 1.15) 1.14 (1.14 to 1.15) 1.14 (1.13 to 1.14)
Standard deviation of blood pressure (per 10 unit increase) NA NA 1.11 (1.09 to 1.12)
NA=not applicable; HDL=high density lipoprotein.
Includes chronic kidney disease (stage 4 or 5) fractional polynomial terms for age (age-1 and age3) and body mass index (BMI−2 and BMI−2ln(BMI)), and interactions with age for body mass index, 
systolic blood pressure, Townsend score, family history of coronary heart disease, treated hypertension, atrial fibrillation, type 1 diabetes, type 2 diabetes, chronic kidney disease, and smoking 
status.
†Same as model A with chronic kidney disease (stage 3, 4, or 5), extra variables listed in table, and additional age interactions for: migraine, corticosteroid use, and erectile dysfunction.
‡Same as model B but with standard deviation of systolic blood pressure.
§Interaction with age; hazard ratios evaluated at mean age.
table 5 | Mean (95% confidence interval) performance of models a, b, and C in the validation cohort in women and men aged 25-84 years
statistic
Model a Model b Model C
Women Men Women Men Women Men
D statistic* 2.48 (2.46 to 2.50) 2.25 (2.24 to 2.27) 2.48 (2.46 to 2.50) 2.26 (2.24 to 2.27) 2.49 (2.47 to 2.51) 2.26 (2.25 to 2.28)
Harrell's C* 0.879 (0.878 to 0.880) 0.858 (0.856 to 0.859) 0.880 (0.878 to 0.881) 0.858 (0.857 to 0.859) 0.880 (0.879 to 0.882) 0.858 (0.857 to 0.860)
R2 (%)† 59.6 (59.2 to 60.0) 54.8 (54.4 to 55.1) 59.5 (59.2 to 59.9) 54.8 (54.5 to 55.2) 59.6 (59.3 to 60.0) 55.0 (54.6 to 55.3)
*A measure of discrimination. Higher values indicate better discrimination.
†Measures explained variation in time to diagnosis. Higher values indicate more variation is explained.
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owing to between practice heterogeneity) was 93.3%. 
The approximate 95% prediction interval for the true C 
statistic in women in a new practice was 0.79 to 0.96. 
The summary C statistic for men was 0.851 (95% confi-
dence interval, 0.847 to 0.855) from a random effects 
meta-analysis. The I2 value was 84.2%. The  approximate 
95% prediction interval for the true C statistic in men in 
a new practice was 0.79 to 0.91.
Calibration
In women, the mean 10 year predicted risk was 4.7% for 
models A, B, and C. The observed 10 year risk was 5.8% 
(95% confidence interval 5.8% to 5.9%). In men, the 
mean 10 year predicted risk was 6.4% for models A, B, 
and C. The observed 10 year risk was 7.5% (7.5% to 7.6%). 
Figure 2 shows the mean predicted risks and observed 
risks at 10 years by 10th of predicted risk, applying each 
algorithm to all women and men in the validation 
cohort and to separate age groups (25-39, 40-59, and 
60-84 years). There was close correspondence between 
the mean predicted risks and the observed risks within 
each model 10th overall and in each age group in 
women and men indicating that the algorithms were 
well calibrated. The exception was in those aged 25-39 
where mean predicted risks were slightly higher than 
observed risks.
reclassification
Overall, there were 2 671 298 patients in the validation 
cohort. Of these, 458 263 (17.2%) had a 10 year risk score 
of 10% or greater using model A; 458 869 (17.2%) using 
model B, and 458 868 (17.2%) using model C.
Using model A, the number of patients with a 10 year 
risk score of 15% or more was 308 130 (11.5%) and with 
a risk of 20% of more was 214 451 (8.0%). The corre-
sponding numbers for models B and C were similar.
Of 458 263 patients with a 10 year predicted risk score of 
10% or more using model A, 10 948 (2.4%) would be 
reclassified as low risk (predicted risk <10% over 10 years) 
using model B. The 10 year observed risk among these 
reclassified patients was 10.3% (95% confidence interval 
9.6% to 11.1%), just above the 10% threshold. Conversely, 
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table 6 | Clinical examples update with new models
Characteristics
examples
1 2 3 4 5 6
Sex Male Male Male Female Female Male
Age (years) 44 45 48 55 61 48
Body mass index 27.2 22.4 29.7 24.9 33.7 30
Total cholesterol: HDL cholesterol ratio 6.1 6.3 5 3.2 4.8 4.2
Systolic blood pressure 130 115 124 130 155 140
Ethnic origin White White White White Black African White
Smoking status Heavy smoker Non-smoker Light smoker Moderate smoker Former smoker Non-smoker
Family history of coronary heart disease No No No Yes No No
Type 1 diabetes No No No No No No 
Type 2 diabetes No Yes No No No No 
Treated hypertension No No No No No Yes 
Rheumatoid arthritis No No No No No No 
Atrial fibrillation No No No No No No 
Chronic kidney disease (stage 3, 4, or 5) No No No No No No 
Migraine Yes No Yes No No Yes
Corticosteroid use No No Yes No No No 
Systemic lupus erythematosus No No No No No No 
Atypical antipsychotic use No No No No Yes No 
Severe mental illness No No No No Yes No 
Erectile dysfunction or treatment No Yes No NA NA No 
Standard deviation of systolic blood pressure 6 40 3.1 22 33 No 
Model A 10 year predicted risk 9.2 8.3 6.4 11 9.4 9.2
Model B 10 year predicted risk 11 9.9 11 10 13 11
Model C 10 year predicted risk 11 13 11 11 15 9.5
NA=not applicable HDL=high density lipoprotein.
Fig 1 | Funnel plots of 
discrimination performance 
(harrell’s C statistic) across 
328 general practices
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of the 2 213 035 classified as low risk (predicted risk <10% 
over 10 years) using model A, 11 554 (0.5%) would be 
reclassified as high risk using model B. The 10 year 
observed risk among these reclassified patients was 
12.2% (11.4% to 13.1%), above the 10% threshold.
Of the 458 869 patients with a 10 year predicted risk 
score of 10% or more using model B, 9102 (2.0%) would 
be reclassified as low risk using model C. The 10 year 
observed risk among these reclassified patients was 
9.6% (95% confidence interval 8.9% to 10.5%), margin-
ally below the 10% threshold. Conversely, of the 
2  213 429 with a 10 year predicted risk score of less than 
10% using model B, 9101 (2.4%) would be reclassified as 
high risk using model C. The 10 year observed risk 
among these reclassified patients was 10.7% (9.9% to 
11.6%), marginally above the 10% threshold.
Clinical examples
Table 6  shows clinical examples where use of model A, 
B, or C would result in a reclassification above or below 
the 10% threshold. Figures 3  and 4 show screenshots of 
the updated web calculator with a clinical example 
which can be found at www.qrisk.org.
discussion
We have developed and validated updated algorithms 
(QRISK3) to predict 10 year risk of cardiovascular dis-
ease in women and men aged 25-84 years. The algo-
rithms incorporate established predictor variables from 
QRISK2 as well as new variables associated with 
increased risk of cardiovascular disease. These include 
an expanded definition of chronic kidney disease to 
include chronic kidney disease stage 3, migraine, corti-
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Fig 2 | Predicted and 
observed 10 year 
cardiovascular disease risk 
by 10th of predicted risk
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costeroid use, systemic lupus erythematosus (SLE), 
atypical antipsychotic use, severe mental illness, erec-
tile dysfunction, and a measure of blood pressure vari-
ability (standard deviation of repeated values). We have 
produced three main final models: model A, which 
includes the same variables and coefficients as the cur-
rent version of QRISK2-2017; model B, which includes 
the new variables and the latest systolic blood pressure 
value and is for use where only the current reading is 
available; and our preferred model C, which addition-
ally includes a measure of blood pressure variability 
that may be more suitable for integration into general 
practice computer systems where longitudinal repeated 
values are likely to be available. Although in population 
terms the overall performance of all three models is 
similar, for those who have one or more of the condi-
tions included in the newer models, having the addi-
tional risk taken into account could result in the 
difference between taking or not taking risk reducing 
treatment. The increased complexity is unlikely to 
affect the take-up of the new models as they are 
designed to be calculated automatically from the elec-
tronic patient record.
Comparisons with the literature
The hazard ratios of the new risk variables included in 
our final models are similar in both magnitude and 
direction to those reported in other studies.25
Migraine
Sufficient pathophysiological and epidemiological evi-
dence have now accumulated for some experts to pro-
pose that migraine should be included as a marker for 
future cardiovascular disease.41  Our results support 
this since we found that migraine was associated with a 
36% increased risk of cardiovascular disease for women 
and 29% for men (model B). This is consistent with the 
increased risk of 42% in 27 840 women aged 45 and over 
in the Women’s Health Study42  and the increased risk of 
50% reported in a recent study of 115 541 women aged 
25-42 recruited to the Nurses’ Health Study II.25  In our 
study, migraine was recorded in 6.4% of women and 
Your results
Welcome to the QRISK®3-2017 risk calculator
About you
Clinical information
Age (25-84):
Sex:
UK postcode: leave blank if unknown
Ethnicity:
This calculator is only valid if you do not already have a diagnosis
Postcode:
44
White or not stated
Reset Copyright Algorithm
Your risk of having a heart attack or stroke within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
23 are likely to have a heart attack or stroke within the next 10 years.
Your score has been calculated using estimated data, as some
information was le blank.
Your body mass index was calculated as 31.22 kg/m2.
22.5%
Risk of a heart attack or stroke
Male Female
Smoking status: Heavy smoker (20 or over)
Diabetes status:
Angina or heart attack in a 1st degree relative <60?
Chronic kidney disease (stage 3, 4, or 5)?
Atrial brillation?
On blood pressure treatment?
Do you have migraines?
Rheumatoid arthritis?
Systemic lupus erythematosus (SLE)?
Severe mental illness?
On atypical antipsychotic medication?
Are you on regular steroid tablets?
A diagnosis of or treatment for erectile dysfunction?
None
Body mass index
Height (cm):
Leave blank if unknown
Total cholesterol: HDL cholesterol ratio: 2
Calculate risk
165
Weight (kg): 85
Systolic blood pressure (mm Hg):
Standard deviation of at least two most
recent systolic blood pressure readings
(mm Hg):
132
10
Fig 3 | 10 year risk of 22.5% 
based on model C for a 
white man, aged 44, heavy 
smoker, total cholesterol: 
high density lipoprotein 
(hDl) cholesterol ratio of 2, 
systolic blood pressure of 
132 mm hg, standard 
deviation of systolic blood 
pressure of 10 mm hg, body 
mass index of 31.22, atrial 
fibrillation, erectile 
dysfunction, migraine, and 
steroid use
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2.7% of men. This is less than the 16% reported in the 
Nurse’s Health Study II25  and the 18.4% in the Women’s 
Health Study42  and might reflect differences in cohort 
selection, clinical setting, consulting patterns, diagnos-
tic criteria, or recording of diagnoses. For example, our 
study is based on routinely collected health records and 
uses diagnoses recorded by clinicians before entry to 
the cohort. In contrast, the Nurses’ Health Study II used 
self report questionnaires at three time points over a six 
year period. Our study, which also includes men, is 
much larger than previous studies.25 42  While our study 
may be more representative of the general population 
than patients recruited to a trial, it is also susceptible to 
ascertainment bias. This would be the case if not all 
patients with migraine visited their general practitioner 
and not all of those diagnoses are recorded. Conversely, 
the Nurses’ Health Study II and the Women’s Health 
Study may be subject to recall bias owing to the use of 
self reported questionnaires inquiring about historical 
diagnoses. Also, our definition of migraine included a 
range of subtypes so it is not possible to say which of 
these are associated with the additional risk of being 
categorised as having migraine. For example, the bulk 
of the risk could be coming from those with migraine 
with aura rather than other subtypes.43  While the mag-
nitude of the increased risk associated with migraine is 
relatively small at the individual level, it is important at 
the population level since migraine is so prevalent.41 
Hence there is good justification for including clinician 
recorded diagnosed migraine in our new models.
Corticosteroids and antipsychotics
The National Institute for Health and Care Excellence 
guidance states that cardiovascular disease risk scores 
will underestimate cardiovascular risk among people 
who are taking medicines that cause dyslipidaemia 
such as antipsychotic drugs or corticosteroids.20  In line 
with other studies,44  we found evidence to support the 
increased risk with corticosteroids despite simultane-
ous adjustment of lipid levels. Current corticosteroids 
(defined as ≥2 prescriptions, with the most recent one 
within the 28 days before study entry) were prescribed 
Your results
Welcome to the QRISK®3-2017 risk calculator
About you
Clinical information
Age (25-84):
Sex:
UK postcode: leave blank if unknown
Ethnicity:
This calculator is only valid if you do not already have a diagnosis
Postcode:
44
White or not stated
Reset Copyright Algorithm
Your risk of having a heart attack or stroke within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
8 are likely to have a heart attack or stroke within the next 10 years.
Your score has been calculated using estimated data, as some
information was le blank.
Your body mass index was calculated as 31.22 kg/m2.
7.5%
Risk of a heart attack or stroke
Male Female
Smoking status: Heavy smoker (20 or over)
Diabetes status:
Angina or heart attack in a 1st degree relative <60?
Chronic kidney disease (stage 3, 4, or 5)?
Atrial brillation?
On blood pressure treatment?
Do you have migraines?
Rheumatoid arthritis?
Systemic lupus erythematosus (SLE)?
Severe mental illness?
On atypical antipsychotic medication?
Are you on regular steroid tablets?
A diagnosis of or treatment for erectile dysfunction?
None
Body mass index
Height (cm):
Leave blank if unknown
Calculate risk
165
Weight (kg): 85
Systolic blood pressure (mm Hg):
Standard deviation of at least two most
recent systolic blood pressure readings
(mm Hg):
132
0
Total cholesterol: HDL cholesterol ratio: 2
Fig 4 | 10 year risk ratio of 
7.5% based on model C for 
white man, aged 44, heavy 
smoker, total cholesterol: 
high density lipoprotein 
cholesterol ratio of 2, 
systolic blood pressure of 
132 mm hg, standard 
deviation of systolic blood 
pressure of 0, body mass 
index of 31.22, migraine, 
steroid use, no atrial 
fibrillation, and no erectile 
dysfunction
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for 2.4% of women and 1.5% of men and were associ-
ated with an 82% increased cardiovascular risk in 
women and 58% increased risk in men. This is similar to 
the increased risks with corticosteroids found in other 
studies.45 46 However, our definition was relatively sim-
ple (and could be used in clinical practice) but did not 
account for duration of use and dose and so allows for 
substantial heterogeneity in the indications for steroid 
use, and the effect may not apply equally to those with 
different levels of exposure. Similarly, atypical antipsy-
chotic drugs were prescribed to 0.5% of men and 
women and were associated with a 29% increased car-
diovascular risk in women and 15% increased risk in 
men. Both corticosteroids and atypical antipsychotics 
therefore seem to be clinically important variables to 
include in QRISK, taking account of the magnitude of 
the risk and the potential numbers of patients affected.
severe mental illness
The NICE guidance highlights the increased cardiovas-
cular risk associated with severe mental illness,20 
although this is contrary to a recent systematic review 
and meta-analysis, which failed to find sufficient evi-
dence to support this conclusion.47 Our study found 
that 6.8% of women and 4.3% of men had a diagnosis of 
severe mental illness affects and it was associated with 
a 14% increased risk of cardiovascular disease for 
women and a 13% increased risk for men (model B). 
This is independent of the risk associated with atypical 
antipsychotics and hence both factors have been 
included separately as they will have a compound effect 
on cardiovascular risk. Clinicians will now be able to 
provide better information to these patients both about 
interventions to reduce cardiovascular risk and about 
the potential effects of atypical antipsychotics.
sle
The NICE guidance on lipid modification20  highlights 
the increased cardiovascular risk associated with SLE. 
The excess risk is thought to be driven largely by inflam-
mation and an active immunological response.48
Reduction in risk in patients with SLE may need both 
modification of SLE specific factors such as disease 
activity and drug therapy as well as modification of tra-
ditional cardiovascular disease risk factors, although 
the role of anti-inflammatory treatments is not yet 
clear.48  We found that a diagnosis of SLE is associated 
with a 115% increased risk for women and a 55% 
increased risk for men. While SLE is relatively uncom-
mon (affecting 0.1% of women and rarely affecting 
men), the magnitude of the increased risk is high (sub-
stantially higher than rheumatoid arthritis for example) 
particularly at younger ages (hazard ratios were >2 for 
ages ≤45 years). This makes it an important risk factor 
for these patients and is consistent with other studies 
examining cardiovascular outcomes in patients with 
these conditions.48
Chronic kidney disease
The NICE guidance20 states “do not use a risk assess-
ment tool in people with an estimated glomerular 
 filtration rate (eGFR) of less than 60/mL/1.73 m2 and/or 
albuminuria. These people are at increased risk of car-
diovascular disease . . . Atorvastatin should be offered 
to people with CKD [chronic kidney disease].” Our 
expanded definition of chronic kidney disease now 
includes chronic kidney disease stage 3 (eGFR 30-59/
mL/1.73 m2) in addition to stages 4 and 5, in line with 
other published studies.49 This means QRISK3 can be 
used in such patients and will provide them with better 
information to inform their choice about use of statins 
and potentially other non-drug interventions to reduce 
their cardiovascular risk and to “encourage the person 
to participate in reducing their risk” in line with the rec-
ommendations for other patients.
type 1 diabetes
Although the NICE guidance on lipid modification20 
recommends the use of QRISK2 in patients with type 2 
diabetes, it states “do not use a risk assessment tool to 
assess CVD [cardiovascular disease] risk in patients 
with type 1 diabetes.” Instead it recommends that “sta-
tin treatment is offered to all patients with type 1 diabe-
tes who are older than 40 years or have had diabetes for 
more than 10 years or have established nephropathy or 
have other CVD risk factors.” The current model for 
QRISK2 and the models presented in this paper allow 
calculation of cardiovascular risk for patients with type 
1 diabetes. The performance among patients with type 1 
diabetes is good (see table 6 in the web appendix). We 
can see no reason why patients with type 1 diabetes 
should not have similar discussions to other patients 
regarding the risks and benefits of interventions. Use of 
the calculator in patients with type 1 diabetes is 
intended to allow better information to be shared with 
such patients on their cardiovascular risk profile. It may 
identify patients with a risk under 10% who may not 
want to take statins as well as facilitate a discussion on 
a range of interventions to reduce risk, including weight 
loss, blood pressure control, and smoking cessation. 
The performance of the models in patients with type 2 
diabetes was lower than for patients with type 1 diabe-
tes (for example in men with type 2 diabetes Harrell’s 
C=0.70, R2=22.9% compared with Harrell’s C=0.80, 
R2=45.6% in men with type 1 diabetes).
blood pressure variability
Recent studies have suggested that higher blood pres-
sure variability is associated with increased risks of 
stroke26  and other cardiovascular events.50  This may be 
independent of mean blood pressure values,50  although 
the increased risk of cardiovascular events associated 
with blood pressure variability in the recent meta-anal-
ysis by Stevens et al was based on one study of 8811 
patients aged more than 55 years with type 2 diabetes.51 
In our study, both the most recent value at baseline and 
the standard deviation of systolic blood pressure were 
independently associated with increased risk of cardio-
vascular disease, although the addition of the standard 
deviation to the model did not improve discrimination 
or calibration. It may be difficult to implement the 
model with blood pressure variability in a setting where 
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there is no historical information on blood pressure 
available, such as with a web calculator. While the per-
formance and reclassification statistics suggest that its 
inclusion will not make a major difference at a popula-
tion level, there may be some benefit from taking this 
factor into account for those patients with highly vari-
able blood pressure.
erectile dysfunction
The true prevalence of erectile dysfunction is difficult to 
determine, and estimates range from 1% to 100% 
depending on the age of the population and how the 
diagnosis was made.24  Our study indicated that erectile 
dysfunction affected 2.3% of men, but this is likely to be 
an underestimate as it includes only men who present 
to their doctor with the condition and have the diagno-
sis or treatment recorded on their electronic record. We 
showed that erectile dysfunction is likely to be an inde-
pendent risk factor for cardiovascular disease and was 
associated with a 25% increased risk of cardiovascular 
disease (at the mean age), which is compatible with the 
findings of a meta-analysis that examined the associa-
tion between erectile dysfunction and cardiovascular 
disease risk in 13 studies.23 While the overall relative 
risk estimate from these studies was 1.44, the 95% con-
fidence interval was broad (1.27 to 1.63) and there was 
substantial heterogeneity across the studies. The asso-
ciation was reduced to 1.34 (1.17 to 1.54) when only high 
quality studies were included. Our definition and oth-
ers only provide a summary effect and it should be rec-
ognised that the causes of erectile dysfunction are 
usually a combination of the physiological and psycho-
logical and that men with vascular causes are likely to 
be at higher risk of cardiovascular disease than those 
for whom the cause is largely psychological.
hiv/aiDs
Data from large cohorts have reported that people 
infected with HIV have approximately 50% greater risk 
of acute myocardial infarction and stroke compared 
with those without HIV,52  which may be related to 
antiretroviral treatment.53 While we found a tendency 
towards an increased risk of cardiovascular disease 
among people with HIV/AIDS this did not reach statisti-
cal significance at the 0.01 level so was not included in 
the final models. These results may reflect the relatively 
small numbers with HIV/AIDS recorded on the general 
practice clinical system. Also, people with HIV/AIDS 
tend to be younger and so have low absolute event rates 
and shorter periods of follow-up with an individual gen-
eral practice, which may tend to underestimate the long 
term association. People with HIV/AIDS may receive 
healthcare (and prescriptions for antiretroviral treat-
ment) from specialist clinics rather than general prac-
tices, which may explain why there are few prescriptions 
recorded for antiretroviral treatment on the QResearch 
database. Over time the recording of HIV/AIDS and pre-
scribing of antiretroviral treatment may increase and so 
it is important to reassess the suitability of HIV/AIDS for 
inclusion in QRISK3 periodically to ensure that affected 
people have accurate cardiovascular risk assessments.
Comparison with the original version of QrisK2, 2008
Our new models are well calibrated when applied to a 
separate validation cohort and have high levels of dis-
crimination. We found an improvement in performance 
from all three models over the original version of 
QRISK2 from 2008,28 although some of this improve-
ment is likely to be owing to the wider age range (25-84 
compared with 35-74 years). Since 2008, improvements 
have been made to the underlying QResearch database 
used to derive the QRISK algorithm, which may have 
resulted in improvements to the performance of the 
algorithm over and above extending the age range from 
35-74 to 25-84 years and the inclusion of additional vari-
ables. Ascertainment of cardiovascular events has 
improved with the linkage of the QResearch database to 
both Office for National Statistics mortality and Hospi-
tal Episode Statistics since 1998. The number of prac-
tices contributing to the database has more than 
doubled, from 531 in 2008 to over 1300. The size of the 
derivation cohort has increased fivefold, with 363 565 
cardiovascular events arising from 50.8 million person 
years of observation compared with 96 709 events aris-
ing from 10.9 million person years in 2008. The record-
ing of self assigned ethnic origin has increased; 25% in 
2008 compared with 62% in the current derivation 
cohort. As a result of these factors, there are many more 
events within each ethnic group—for example, there 
has been a 10-fold increase in the number of cardiovas-
cular events for non-white ethnic groups compared 
with 2008. This is reflected in the more accurate hazard 
ratios with tighter confidence intervals and improved 
performance statistics.
strengths and limitations of this study
The methods used to derive and validate these models 
are broadly the same as for a range of other clinical risk 
prediction tools derived from the QResearch data-
base.28 54-57  The strengths and limitations of the 
approach have already been discussed in detail.8 54 57-60 
In summary, key strengths include size, duration of fol-
low up, representativeness, and lack of selection, 
recall, and respondent bias. UK general practices have 
good levels of accuracy and  completeness in recording 
clinical diagnoses and prescribed drugs.61 We think our 
study has good face validity since it has been conducted 
in the setting where most patients in the UK are 
assessed, treated, and followed up. Limitations of our 
study include the lack of formal adjudication of diagno-
ses, information bias, and potential for bias owing to 
missing data. Our database has linked hospital and 
mortality records for nearly all patients and is therefore 
likely to have picked up the majority of cardiovascular 
events thereby minimising ascertainment bias. We 
excluded patients using statins at baseline as in previ-
ous versions of QRISK and QRISK2. Over the past 
decade a change in guidelines will have led to a higher 
proportion of at risk patients being prescribed statins in 
the absence of established cardiovascular disease. 
Removing patients at high risk will tend to lower overall 
event rates. We excluded patients without a valid depri-
vation score since this group may represent a more 
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 transient population, where follow-up could be unreli-
able or unrepresentative. Their deprivation scores are 
unlikely to be missing at random so we did not think it 
would be appropriate to impute them. Given the num-
ber tested for inclusion, there may be some over fitting 
of interaction terms. We have continued to use the well 
recognised total cholesterol: high density lipoprotein 
cholesterol ratio as a predictor rather than low density 
lipoprotein cholesterol values alone as the ratio 
resulted in improved prediction during earlier versions 
of QRISK and QRISK2 and is measured directly, whereas 
low density lipoprotein cholesterol is calculated.
The present validation has been done on a separate 
set of practices and individuals to those that were 
used to develop the score, although the practices all 
use the same general practice clinical computer sys-
tem (EMIS, used by 55% of UK general practices). An 
independent validation study would be a more strin-
gent test and should be done, but when such indepen-
dent studies have examined QRISK2 and other risk 
algorithms,6 7 59 60  they have shown comparable per-
formance compared with the validation in the QRe-
search database.28 54 58 We have published the source 
code to enable accurate implementation of QRISK3 on 
the QRISK website (www.qrisk.org) with earlier ver-
sions of the score from previous annual updates. The 
rationale for this is to ensure that those interested in 
reviewing or using the open source will then be able 
to find the current version as the score continues to be 
updated.
Conclusion
We have developed updated algorithms (QRISK3) to 
quantify absolute risks of cardiovascular disease in 
people aged 25-84 years, which include established risk 
factors and new risk factors: expanded definition of 
chronic kidney disease (stage 3, 4, or 5), migraine, cor-
ticosteroid use, SLE, atypical antipsychotic use, severe 
mental illness, erectile dysfunction, and a measure of 
blood pressure variability (standard deviation of 
repeated measures). The updated risk algorithms pro-
vide valid measures of absolute risk in the general 
 population of patients, as shown by the performance in 
a separate validation cohort.
A simple web calculator to implement the QRISK3 algorithms can be 
accessed at www.qrisk.org/Open source software is also available for 
download.
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